Recently, photo-sensitive moieties have also been incorporated to platinum complexes for the development of photo-activated cancer chemotherapy or (pro)drug delivery. Platinum(II) porphyrins ...

For these reasons I believe that all the physicians and researchers involved in the care of cancer patients or in the development of new platinum-based drugs should be fully aware of the potential ...

Project lead at RMIT, Distinguished Professor Suresh Bhargava AM, said it marked a promising step towards alternatives to platinum-based cancer drugs. "These newly synthesized compounds ...

It explains that, with the World Health Organisation estimating that new cancer cases could rise by 50% by 2040, platinum-based drugs will be pivotal to efficient and effective treatments ...

TEVIMBRA is a uniquely designed humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is ...

CUSP06 has a drug-to-antibody ratio of eight. OnCusp obtained the exclusive global rights (outside of China) to lead the development and commercialization of CUSP06 from Multitude Therapeutics in 2022 ...